Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medco’s Washington D.C. office

Executive Summary

Medco is searching for a head of its new Washington, D.C. office, which could open as early as November. Merck's Washington office currently handles Medco's federal lobbying, but Merck plans to spin off the pharmacy benefit management subsidiary, which could also happen in November (1"The Pink Sheet" Sept. 23, In Brief)...

You may also be interested in...



Medco D.C. office begins with Begans

Former Prudential government relations exec Peter Begans will head Medco's new Washington, D.C. office as VP-federal government affairs, company announces Nov. 13. Begans was previously communications director for former New Jersey Governor Thomas Kean (R). The PBM's lobbying staff is being set up in advance of a spinoff by Merck (1"The Pink Sheet" Nov. 4, In Brief)...

Medco IPO plans

Merck pharmacy benefit management subsidiary is understood to be looking for a November date to complete its delayed initial public offering. Medco Health Solutions withdrew its IPO registration in July, citing market conditions (1"The Pink Sheet" July 15, p. 28). Company has pledged to complete the IPO by summer 2003 at the latest...

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel